Home
/

Menopause

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Key takeaway:

Menopause blood testing measures FSH, LH, estradiol, and progesterone to make the brain–ovary feedback loop visible—confirming menopausal transition as ovarian follicle reserve declines and pituitary signaling rises. After menopause, FSH and LH rise above reproductive ranges while estradiol and progesterone fall, connecting ovarian aging to bone density, lipid profiles, and vascular function for evidence-based hormone therapy and surveillance decisions.

Read more →
Table of contents

Menopause and the Hormonal Shift Behind It

Menopause biomarkers are blood signals that track the winding down of ovarian function. They come from the ovaries and the brain’s hormone control center (pituitary) and reflect how many follicles remain and how actively they respond. Key markers include estrogen made by the ovaries (estradiol), pituitary messengers that stimulate the ovaries (follicle-stimulating hormone, FSH; luteinizing hormone, LH), ovarian growth signals that fade as egg supply declines (anti-Müllerian hormone, AMH), and ovarian feedback proteins (inhibin B). Together they map the feedback loop that steadies the menstrual cycle. As that loop loosens, levels shift in characteristic ways, revealing the transition from regular cycling to perimenopause and menopause. Testing helps distinguish menopausal change from other look-alike causes of symptoms, times conversations about contraception and symptom care, and anchors decisions about therapies. Because hormones fluctuate, patterns over time are often more telling than a single snapshot, turning biomarkers into a practical compass for where you are in the reproductive lifespan.

Why a Hormone Read Sometimes Helps the Conversation

Menopause blood biomarkers map the shifting conversation between brain and ovaries that influences nearly every system—thermoregulation, sleep, mood, cognition, bone turnover, cardiovascular and metabolic health, and urogenital tissues. Measuring FSH, LH, estradiol, and progesterone makes that invisible transition visible.In cycling years, FSH and LH usually sit in the low-to-middle part of the lab range outside of ovulation, estradiol tends to fall in the mid-range across the follicular phase, and progesterone peaks toward the high end in the luteal phase. Through perimenopause, values swing widely. After menopause, FSH and LH are typically above the reproductive reference range, while estradiol and progesterone fall below it. During pregnancy, by contrast, FSH and LH are very low and estradiol and progesterone are high—helpful context when timing tests.When estradiol and progesterone drop, the hypothalamus loses its usual feedback and FSH/LH rise; low sex-steroid levels drive hot flashes, night sweats, irregular or absent periods, vaginal dryness and discomfort, reduced libido, sleep fragmentation, mood shifts, and brain “fog.” Lower estrogen accelerates bone resorption, raises LDL cholesterol, and can worsen insulin sensitivity, affecting long-term bone and heart health. If FSH and LH are unexpectedly low in the setting of menopausal symptoms, that pattern points away from ovarian aging and toward central (pituitary–hypothalamic) causes.Big picture: these hormones are the front door to a broader systems check. They connect ovarian aging to bone density, lipid profiles, vascular function, and cognitive and urogenital health, helping clarify stage (peri vs post) and informing surveillance for osteoporosis and cardiovascular risk over time.

What Hormone Testing Adds — and Where Clinical Judgment Leads

Menopause blood testing provides a window into the hormonal shifts that shape a woman’s health as she transitions out of her reproductive years. These changes affect not only fertility, but also energy levels, metabolism, cardiovascular risk, bone strength, cognitive function, and immune balance. At Superpower, we measure four key biomarkers—FSH (follicle-stimulating hormone), LH (luteinizing hormone), estradiol, and progesterone—to map this transition and its impact on the body’s interconnected systems.FSH and LH are hormones produced by the pituitary gland that regulate the menstrual cycle and ovulation. Estradiol and progesterone are ovarian hormones essential for reproductive function, but they also influence brain health, bone density, and cardiovascular stability. As menopause approaches, the ovaries gradually produce less estradiol and progesterone. In response, FSH and LH levels rise, signaling the body’s attempt to stimulate ovarian hormone production.Tracking these biomarkers helps clarify where someone is in the menopausal transition. Persistently high FSH and LH, alongside low estradiol and progesterone, indicate that the ovaries have reduced hormone output—a hallmark of menopause. This hormonal pattern reflects a new physiological balance, affecting everything from sleep and mood to bone and heart health.Interpretation of menopause blood tests depends on several factors, including age, menstrual history, pregnancy status, certain medications (like hormone therapy), and acute illness. Laboratory methods and reference ranges can also vary, so results are best understood in the context of the individual’s overall health and life stage.

FAQs

Menopause blood testing checks the hormonal signals that control the ovarian–pituitary system. Superpower measures FSH and LH (pituitary gonadotropins), and estradiol and progesterone (ovarian hormones). As the ovaries lose follicles, estradiol and progesterone fall and the pituitary drives FSH (and to a lesser extent LH) higher. One sample gives a snapshot; repeated testing shows trend. Results help distinguish normal cycling, perimenopause (fluctuating hormones), and menopause (persistently low ovarian hormones with elevated FSH).

Testing adds objective data about where your reproductive system is on the menopause transition. It helps explain cycle changes, hot flashes, sleep or mood shifts, and low libido by showing whether ovarian hormone output is falling and pituitary drive is rising. It’s especially useful if you have irregular or absent periods, had a hysterectomy, are under 45 with symptoms, or are using hormonal contraception or HRT where cycle clues are masked.

Yes. With Superpower, our team member can organize a blood draw in your home.

Hormones fluctuate widely in perimenopause, so a single value can mislead. If you’re still cycling, consider repeating every 3–6 months to see a clear trend. Two results showing persistently high FSH with low estradiol several weeks to months apart support menopause. If you’ve had 12 months without a period and aren’t on hormones, further testing is rarely needed. If you’re using hormonal therapy or contraception, timing relative to dosing matters and results reflect the medication.

Hormonal contraception and HRT suppress or replace native hormones, lowering FSH/LH and altering estradiol/progesterone. Pregnancy, breastfeeding, and recent ovulation shift levels, especially progesterone. Cycle day matters if you still menstruate. Acute illness, major stress, thyroid or pituitary disorders, ovarian surgery, chemotherapy, and significant weight change can alter results. Smoking may advance menopause. High-dose biotin supplements can interfere with some assays. Different labs and methods have different reference ranges.

No fasting is needed. Morning collection improves consistency. If you still have periods, baseline pituitary–ovarian signaling is best assessed early in the cycle (days 2–5). Tell us about any hormonal contraception, HRT, or fertility treatments—your results will reflect these therapies rather than your natural baseline. Avoid high-dose biotin supplements for 48–72 hours before testing to reduce assay interference.

References

  1. Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause, 19(4), 387-395. https://doi.org/10.1097/gme.0b013e31824d8f40
  2. Burger, H. (2008). The menopausal transition--endocrinology. The Journal of Sexual Medicine, 5(10), 2266-2273. https://doi.org/10.1111/j.1743-6109.2008.00921.x
  3. Su, H. I., & Freeman, E. W. (2009). Hormone changes associated with the menopausal transition. Minerva Ginecologica, 61(6), 483-489. https://pubmed.ncbi.nlm.nih.gov/19942836/
  4. Matthews, K. A., Chen, X., Barinas-Mitchell, E., Brooks, M. M., Derby, C. A., Harlow, S., Jackson, E. A., Thurston, R. C., & El Khoudary, S. R. (2021). Age at menopause in relationship to lipid changes and subclinical carotid disease across 20 years: Study of Women's Health Across the Nation. Journal of the American Heart Association, 10(18), e021362. https://doi.org/10.1161/JAHA.121.021362
  5. Weitzmann, M. N., & Pacifici, R. (2006). Estrogen deficiency and bone loss: An inflammatory tale. The Journal of Clinical Investigation, 116(5), 1186-1194. https://doi.org/10.1172/JCI28550

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey